Drug Resistance Reversal Potential of Nanoparticles/Nanocomposites via Antibiotic’s Potentiation in Multi Drug Resistant <i>P. aeruginosa</i>
Pratima Pandey,
Rajashree Sahoo,
Khusbu Singh,
Sanghamitra Pati,
Jose Mathew,
Avinash Chandra Pandey,
Rajni Kant,
Ihn Han,
Eun-Ha Choi,
Gaurav Raj Dwivedi,
Dharmendra K. Yadav
Affiliations
Pratima Pandey
Department of Biotechnology, Bundelkhand University, Jhansi 284128, India
Rajashree Sahoo
Microbiology Department, ICMR-Regional Medical Research Centre, Bhubaneshwar 751023, India
Khusbu Singh
Microbiology Department, ICMR-Regional Medical Research Centre, Bhubaneshwar 751023, India
Sanghamitra Pati
Microbiology Department, ICMR-Regional Medical Research Centre, Bhubaneshwar 751023, India
Jose Mathew
Department of Biotechnology, Bundelkhand University, Jhansi 284128, India
Avinash Chandra Pandey
Nanotechnology Application Centre, University of Allahabad, Allahabad 211002, India
Rajni Kant
Microbiology Department, ICMR-Regional Medical Research Centre, Gorakhpur 273013, India
Ihn Han
Plasma Bioscience Research Center, Applied Plasma Medicine Center, Department of Electrical & Bio-logical Physics, Kwangwoon University, Seoul 01897, Korea
Eun-Ha Choi
Plasma Bioscience Research Center, Applied Plasma Medicine Center, Department of Electrical & Bio-logical Physics, Kwangwoon University, Seoul 01897, Korea
Gaurav Raj Dwivedi
Microbiology Department, ICMR-Regional Medical Research Centre, Gorakhpur 273013, India
Dharmendra K. Yadav
College of Pharmacy, Gachon University, Hambakmoeiro 191, Yeonsu-gu, Incheon City 406-799, Korea
Bacteria employ numerous resistance mechanisms against structurally distinct drugs by the process of multidrug resistance. A study was planned to discover the antibacterial potential of a graphene oxide nanosheet (GO), a graphene oxide–zinc oxide nanocomposite (GO/ZnO), a graphene oxide-chitosan nanocomposite (GO–CS), a zinc oxide decorated graphene oxide–chitosan nanocomposite (GO–CS/ZnO), and zinc oxide nanoparticles (ZnO) alone and in a blend with antibiotics against a PS-2 isolate of Pseudomonas aeruginosa. These nanocomposites reduced the MIC of tetracycline (TET) from 16 folds to 64 folds against a multidrug-resistant clinical isolate. Efflux pumps were interfered, as evident by an ethidium bromide synergy study with nanocomposites, as well as inhibiting biofilm synthesis. These nanoparticles/nanocomposites also decreased the mutant prevention concentration (MPC) of TET. To the best of our knowledge, this is the first report on nanomaterials as a synergistic agent via inhibition of efflux and biofilm synthesis.
